Estrella Immunopharma, Inc.
ESLA · XNASCIK 1844417fmd_1PMRP0C8J1SYXEHQAK694VHCYYManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 06, 2021 to Jun 30, 2026, 22 periods
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Realized investment gains (losses) | 0 | 1 | – | – | – |
| Research and development | – | – | 10 | 4 | 10 |
| Total operating expenses | – | – | 11 | 7 | 13 |
| Operating income | (0) | (2) | – | (7) | (13) |
| Interest and investment income | 0 | 1 | – | – | – |
| Income before taxes | (0) | (1) | – | (7) | (13) |
| Income tax expense | 0 | 0 | – | 0 | 0 |
| Net income from continuing operations | (0) | (1) | – | (7) | (13) |
| Net income | (0) | (1) | – | (7) | (13) |